To determine the optimal dosage of ICAM‐1‐Dxd, its antitumor efficacy was evaluated in 4T1 tumor‐bearing mice model using escalating doses (1, 5, or 10 mg kg−1) administered via tail vein injection. The gene discussed is ICAM1; the disease is neoplasm.